OIG Tells FDA to Monitor Clinical Investigators’ Financial Ties for Conflicts of Interest

Sponsors of clinical trials may receive greater scrutiny of their financial ties to clinical investigators following an HHS Office of Inspector General (OIG) report recommending the agency require sponsors to submit investigators’ complete financial information in pretrial applications, and ensure its staff document their reviews and take appropriate action.
Washington Drug Letter